ReviewInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2025
Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.
Review in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07509814 (Efficacy of an Extended Prehabilitation Program Versus Standard in Patients With Advanced Ovarian Cancer Within ERAS Protocols), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of an Extended Prehabilitation Program Versus Standard in Patients With Advanced Ovarian Cancer Within ERAS Protocols
Who cites it
22 citing papers in PubMed.
- α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Article
- Context-dependent roles of HtrA2/Omi in ovarian cancer: mitochondrial apoptotic function linking platinum sensitivity and acquired chemoresistance-a narrative review.Translational cancer research · 2026Review
- Article
- Predictive factors for long-term survivors in advanced-stage epithelial ovarian cancer.AJOG global reports · 2026Article
- Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery.Cancers · 2026Review
- Predictors of postoperative morbidity and delayed initiation of adjuvant chemotherapy after cytoreductive surgery in advanced-stage epithelial ovarian cancer.World journal of surgical oncology · 2026Article
- Comparison of [Abdominal radiology (New York) · 2026Article
- Immune-mediated colitis associated with trastuzumab deruxtecan in ovarian cancer: a case report and rechallenge experience.Gynecologic oncology reports · 2026Article
- Diagnostic Consistency and Morphological Limits of Extraovarian Lesions in Ovarian Serous Tumors: A Comparative Study Between Gynecological and General Pathologists.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- The Impact of the Number of Neoadjuvant Chemotherapy Cycles on Outcomes in Advanced Ovarian Cancer: A Narrative Review.Cancers · 2026Review
- Salpingo-oophorectomy for twisted ovarian dysgerminoma in a prestigious pregnancy: challenges and outcomes. A case report.International journal of surgery case reports · 2026Article
- A clinicopathological study of borderline ovarian tumors: insights from a tertiary care center in Saudi Arabia.BMC women's health · 2026Article
- Article
- Advances in adoptive cell therapy for ovarian cancer.Frontiers in immunology · 2026Review
- Claudin-4 Overexpression Predicts Poor Survival and Platinum Resistance in Epithelial Ovarian Cancer: A Potential Biomarker for Clinical Decision-Making.Diagnostics (Basel, Switzerland) · 2025Article
- From Inflammation to Malignancy: The Link Between Endometriosis and Gynecological Cancers.International journal of molecular sciences · 2025Review
- Altered Apoptosis in Endometriosis Compared with Ovarian Carcinoma.Medicina (Kaunas, Lithuania) · 2025Article
- FIGO Cancer Report 2025: Transforming gynecologic oncology through global equity, technological innovation, and preventive strategies.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSCs). Stage IC is now divided into three categories: IC1 (surgical spill), IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface), and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension) and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, including the treatment of ovarian germ cell and stromal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.